Delivery Order SPE2DB22D1052-SPE2DB25FU9XC
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Onfil 10 mg tablets (100-count) under a firm fixed-price contract with a ceiling value of $7,471.73. This non-set-aside award is classified as a delivery order with an ultimate completion date of August 22, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a specific pharmaceutical supply requirement within the...
- The Defense Logistics Agency awarded a delivery order valued at $1,884.13 to AmerisourceBergen Drug Corp for 100 tablets of Onfil 10 mg, with delivery scheduled for completion by September 11, 2025. The contract was awarded on September 10, 2025, under a firm fixed-price arrangement with no set-aside designation, indicating competitive award. Performance will take place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $9,737.35 to AmerisourceBergen Drug Corp for Onfil 10 mg tablets (100 count) on August 11, 2025, with completion scheduled for August 12, 2025. This non-set-aside contract employs firm fixed pricing under a delivery order contract type and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Onfil 10 mg tablets (100 count) with a ceiling value of $3,064.78. This competitively awarded, non-set-aside contract is structured as a firm fixed price delivery order with an ultimate completion date of July 23, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,422.19 to AmerisourceBergen Drug Corp for 100 tablets of Onfil 10 mg on August 4, 2025, with completion scheduled for August 5, 2025. This competitively awarded contract utilizes firm fixed price terms with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the delivery at its corporate office location in Conshohocken, PA 19428....
- The Defense Logistics Agency awarded a delivery order valued at $2,130.37 to AmerisourceBergen Drug Corp for 100 tablets of Onfil 10 mg on September 3, 2025, with completion scheduled for September 4, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. The delivery order represents a routine pharmaceutical procurement supporting federal medical supply requirements....
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Onfil 10 mg tablets (100-count units) with a ceiling value of $4,414.14. This competitive, non-set-aside award reflects a firm fixed-price delivery order placed against AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical (SPE2DX), valued at $999.99 million and extending through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order valued at $6,011.68 to AmerisourceBergen Drug Corp for 100 tablets of Onfil 10 mg on September 3, 2025, with completion targeted for September 4, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,859.99 for 100 tablets of Onfil 10 mg on August 19, 2025, with an ultimate completion date of August 20, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and is being performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen Drug Corp's prime Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Onfil 10 mg tablets (100-count units) with a ceiling value of $3,109.20. This firm fixed-price, non-set-aside contract is classified as a delivery order with an ultimate completion date of September 5, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement...
- SPE2DB22D1052Indefinite Delivery Contract
- SPE2DB22D1052-SPE2DB25FU9XCDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $10,373.47 to AmerisourceBergen Drug Corp for 100 tablets of Onfil 10 mg on August 21, 2025, with an ultimate completion date of August 22, 2025. This is a firm fixed-price delivery order with no set-aside designation, performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a competitively awarded transaction under the company's existing contract vehicle with DLA. This delivery order is issued under AmerisourceBergen Drug Corp's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. This prime contract vehicle serves as a comprehensive global pharmaceutical support mechanism enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen Drug Corp maintains a significant role in federal medical procurement, particularly for the Defense Health Agency and other government healthcare systems, through its capacity to deliver both brand-name and generic medications across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.4k | 8/21/25 |